| Literature DB >> 35119273 |
Ilyas Berhane, Niyada Hin, Ajit G Thomas, Qian Huang, Chi Zhang, Vijayabhaskar Veeravalli, Ying Wu, Justin Ng, Jesse Alt, Camilo Rojas, Hiroe Hihara1, Mika Aoki1, Kyoko Yoshizawa1, Tomoki Nishioka1, Shuichi Suzuki1, Shao-Qiu He, Qi Peng, Yun Guan, Xinzhong Dong, Srinivasa N Raja, Barbara S Slusher, Rana Rais, Takashi Tsukamoto.
Abstract
Mas-related G protein-coupled receptor X1 (MRGPRX1) is a human sensory neuron-specific receptor and potential target for the treatment of pain. Positive allosteric modulators (PAMs) of MRGPRX1 have the potential to preferentially activate the receptors at the central terminals of primary sensory neurons and minimize itch side effects caused by peripheral activation. Using a high-throughput screening (HTS) hit, a series of thieno[2,3-d]pyrimidine-based molecules were synthesized and evaluated as human MRGPRX1 PAMs in HEK293 cells stably transfected with human MrgprX1 gene. An iterative process to improve potency and metabolic stability led to the discovery of orally available 6-(tert-butyl)-5-(3,4-dichlorophenyl)-4-(2-(trifluoromethoxy)phenoxy)thieno[2,3-d]pyrimidine (1t), which can be distributed to the spinal cord, the presumed site of action, following oral administration. In a neuropathic pain model induced by sciatic nerve chronic constriction injury (CCI), compound 1t (100 mg/kg, po) reduced behavioral heat hypersensitivity in humanized MRGPRX1 mice, demonstrating the therapeutic potential of MRGPRX1 PAMs in treating neuropathic pain.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35119273 PMCID: PMC9176367 DOI: 10.1021/acs.jmedchem.1c01709
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 8.039